Buy Full Version
"Ubiquitin Proteasome Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Ubiquitin Proteasome Market by Application (Scientific Research and Cancer Treatment) - Global Opportunity Analysis and Industry Forecast, 2019-2026

Pharmaceuticals	LI_184224	Pages: NA	Jan 2020 \| 858 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Proteasomes are cellular complexes responsible for protein breakdown. Ubiquitin is a small protein found in all cellular tissues in humans and other eukaryotic organisms that support to regulate the processes of other proteins. Ubiquitin proteasome is a highly regulated mechanism of intracellular protein degradation, by marking proteins that are linked to ubiquitin.

The systems play a vital role in biological functions of the body such as antigen presentation, regulation of gene transcription & the cell cycle, and activation of NF-KB, which is responsible to regulate the immunological response to infections.

The development of ubiquitin proteasomes for treatment of cancer such as multiple myeloma and mantle cell lymphoma majorly drives the market. Increase in use of Ubiquitin Proteasome as a research tool in academic and industrial research center fuels the market growth. In addition, the patent expiry of Velcade (brand name of Ubiquitin Proteasome by Takeda Pharmaceutical Company Ltd) in Nov 2017 is anticipated to boost the market.

However, high cost of the drug and stringent government regulations involved in the production of Ubiquitin Proteasome hinder the growth of the market. In addition, side effects associated with ubiquitin proteasome such as low blood pressure, peripheral neuropathy, heart problems, lung problems, GIT problems, and others also restrain the market. Ongoing R&D activities related to Ubiquitin Proteasome are anticipated to present new opportunities for the market.

The market is segmented on the basis of application and region. Based on application, the market is bifurcated into scientific research and cancer treatment. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the global ubiquitin proteasome market with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

Ubiquitin Proteasome Market Key Segments:

By Application

Scientific Research
Cancer Treatment
- Multiple Myeloma (A Cancer of the Plasma Cells)
- Mantle Cell Lymphoma (A Cancer of the Lymph Nodes)

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa

List of players profiled in the report

Takeda Pharmaceutical Company Ltd
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Novelix Pharmaceuticals, Inc
GlaxoSmithKline Pharmaceuticals Ltd
Onyx Pharmaceuticals, Inc
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Novartis International AG
Glenmark Pharmaceuticals Ltd

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 UBIQUITIN PROTEASOME MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SCIENTIFIC RESEARCH

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CANCER TREATMENT

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Multiple Myeloma

4.3.4.1. Market size and forecast

4.3.5. Mantle Cell Lymphoma

4.3.5.1. Market size and forecast

CHAPTER 5 UBIQUITIN PROTEASOME MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast

5.2.4. North America Ubiquitin Proteasome Market by Application

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast

5.3.4. Europe Ubiquitin Proteasome Market by Application

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. India market size and forecast
5.4.3.4. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Ubiquitin Proteasome Market by Application

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Latin America market size and forecast
5.5.3.2. Middle East market size and forecast
5.5.3.3. Africa market size and forecast

5.5.4. LAMEA Ubiquitin Proteasome Market by Application

CHAPTER 6 COMPANY PROFILES

6.1. TAKEDA PHARMACEUTICAL COMPANY LTD

6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments

6.2. JOHNSON & JOHNSON

6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments

6.3. F. HOFFMANN-LA ROCHE LTD

6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments

6.4. NOVELIX PHARMACEUTICALS, INC

6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments

6.5. GLAXOSMITHKLINE PHARMACEUTICALS LTD

6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments

6.6. ONYX PHARMACEUTICALS, INC

6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments

6.7. TEVA PHARMACEUTICAL INDUSTRIES LTD.

6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments

6.8. MYLAN N.V.

6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments

6.9. NOVARTIS INTERNATIONAL AG

6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments

6.10. GLENMARK PHARMACEUTICALS LTD

6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,041 Data Pack/Excel ~~$3,840~~ $3,379 Single User License ~~$5,370~~ $4,726 Five User License ~~$6,450~~ $5,676 Enterprise User License ~~$8,995~~ $7,916

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com